



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,422	07/03/2001	Rudolf Hauptmann	98,385-H	8840

20306 7590 09/17/2003

MCDONNELL BOEHNEN HULBERT & BERGHOFF  
300 SOUTH WACKER DRIVE  
SUITE 3200  
CHICAGO, IL 60606

EXAMINER

O HARA, EILEEN B

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 09/17/2003

13

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/899,422

Applicant(s)

HAUPTMANN ET AL.

Examiner

Eileen O'Hara

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 25 October 2002.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-53 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-53 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03 July 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All   b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☒ Certified copies of the priority documents have been received in Application No. 07/511,430.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

## **DETAILED ACTION**

### ***Advisory Information***

1. Applicants requested that claims 1-13 and 15-35 be amended in Paper No. 9, filed Oct. 25, 2002. Claims 1-4, 7-13 and 15-35 were amended as requested. However, claims 5 and 6 were not amended, because there was no (Amended) next to the claim numbers. Therefore the official version of the claims are the claims as originally filed. However, the claims will be examined as if they had been amended. Amended versions of claims 5 and 6 should be included in the response to this office action.

### ***Claims Status***

2. Claims 1-53 are pending in the instant application. Claims 1-4, 7-13 and 15-35 have been amended as requested by Applicant in Paper Number 9, filed Oct. 25, 2002. All claims will be examined on the merits.

### ***Specification***

3.1 The substitute specification filed Oct. 25, 2002 has been entered.

3.2 The disclosure is objected to because of the following informalities: On page 6 of the substitute specification filed Oct. 25, 2002, on line 38, Figures "6A-6B" should be "6A-6E" to match the figure.

Appropriate correction is required.

3.3 The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: TNF binding proteins.

Art Unit: 1646

***Information Disclosure Statement***

4. The information disclosure statement filed July 27, 2001 (Paper No. 3) fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. References 34, 92, 107, 118, 120, 121, 134, 146 and 148 were not supplied. Either a duplicate of another paper or a different paper by the same authors was supplied for these references. Therefore those references have not been considered.

***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5.1 Claims 1-53 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 27-76 of copending Application No. 09/792,356. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant application has claims directed to TNF binding proteins, and application 09/792,356 has claims directed towards pharmaceutical compositions comprising the same TNF binding proteins. It would have been *prima facie*

Art Unit: 1646

obvious of one of ordinary skill in the art to make pharmaceutical compositions comprising the TNF binding proteins, in order to administer the polypeptides to individuals in order to ameliorate the effects of TNF.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

5.2 Claims 1-53 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 33 and 34 of U.S. Patent No. 6,271,346. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the instant application are directed to TNF binding proteins, and Patent No. 6,271,346 has claims directed towards pharmaceutical compositions comprising the same TNF binding proteins. It would have been *prima facie* obvious of one of ordinary skill in the art to make pharmaceutical compositions comprising the TNF binding proteins, in order to administer the polypeptides to individuals in order to ameliorate the effects of TNF.

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

5.3 Claims 1-53 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-32 of prior U.S. Patent No. 6,271,346. This is a double patenting rejection.

*Claim Rejections - 35 USC § 112*

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 15-22 and 45-53 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

6.1 Claims 15-22, 45-48 and 50-53 are indefinite because the “at least one” language of the independent claim does not place an upper limit on the extent of the changes to be made. For example, as written, it may be possible to make conservative amino acid substitutions at every amino acid residue and still bind TNF, but the protein would be completely different from those of the recited SEQ ID NOS. Therefore, the claims fail to adequately point out that which Applicant sees as the invention.

6.2 Claim 49 is indefinite because it encompasses a protein encoded by a nucleic acid molecule which hybridizes under “**moderately or highly stringent**” conditions, and there are no hybridization conditions defined in the specification. The term “**moderately or highly stringent**” is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired.

Art Unit: 1646

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7.1 Claims 15-22, 45-48 and 50-53 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making and using a polypeptide comprising the amino acid sequence of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20, which are either full-length protein or truncations/deletions of TNF receptor, does not reasonably provide enablement for making and using polypeptides that have at least one conservative amino acid substitution, substitution at a glycosylation site, substitution at a proteolytic cleavage site, substitution at a cysteine residue, amino acid deletion, insertion, or combinations of the above. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The instant specification discloses a naturally occurring human TNF receptor polypeptide comprising the amino acid sequence presented in SEQ ID NO: 2. This 455 amino acid residue protein is the full length protein, and the specification teaches truncation variants (SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18 and 20) that are soluble and can bind TNF (alignment of sequences in Exhibit A, filed Oct. 15, 2002 in related case 09/525,998). The soluble form of the TNF receptor is amino acids 20-180 of SEQ ID NO: 2 (The Cytokine Facts Book, Second Edition, Academic Press, Fitzgerald et al. editors, page 478), and all of the disclosed truncation variants contain up to amino acid 201 of SEQ ID NO: 2. The core sequence common to all of the polypeptides is SEQ ID NO: 4, and corresponds to amino acids 41-201 of SEQ ID NO: 2. This core sequence (amino acids 41-180 of SEQ ID NO: 2) is therefore a minimum amino acid sequence that still retains TNF binding activity. However, because these claims encompass significant structural changes to the protein, a practitioner can not make a protein comprising

Art Unit: 1646

an amino acid sequence other than the ones disclosed in the instant specification and expect it to have the same functions. Claims that encompass a polypeptide with at least one conservatively substituted amino acid residue, or with at least one addition or deletion of amino acid residues to the amino acid sequences, or combinations thereof, encompass proteins which can vary significantly from the disclosed natural sequences. Specifically, the instant specification does not identify those amino acid residues in the amino acid sequence of SEQ ID NO: 4 which are essential for its biological activity and structural integrity and those residues which are either expendable or substitutable. In the absence of this information a practitioner would have to resort to a substantial amount of undue experimentation in the form of insertional, deletional and substitutional mutation analysis of the amino acid residues before they could even begin to rationally design a functional TNF binding protein having other than a natural amino acid sequence. The disclosure of a natural amino acid core sequence having TNF binding activity is clearly insufficient support under the first paragraph of 35 U.S.C. § 112 for claims which encompass all of the other variants encompassed by the claims.

The current claim limitations are analogous to those of claim 7 of U.S. Patent Number 4,703,008 which were held to be invalid under 35 U.S.C. § 112, first paragraph, for want of enablement in *Amgen Inc. v. Chugai Pharmaceuticals Co. Ltd.*, 18 U.S.P.Q. 2d, 1016 (CAFC, 3/5/91, see page 1026, section D). In that instance, a claim to a nucleic acid encoding a polypeptide having an amino acid sequence sufficiently duplicative of the amino acid sequence of erythropoietin (EPO) so as to have a specified biological activity was held to be invalid under 35 U.S.C. § 112, first paragraph, for want of enablement. The disclosure upon which that claim was based described a recombinant DNA encoding EPO and a few analogs thereof. That disclosure differs from the instant specification because, whereas the instant specification describes a human TNF binding protein it does not describe even a single variant thereof,

Art Unit: 1646

except for the truncation/deletion variants, all of which comprise the same core TNF binding activity.

The court held that what is necessary to support claims of this breadth is a disclosure sufficient to enable one skilled in the art to carry out the invention commensurate with the scope of the claims. For proteins, that means disclosing how to make and use enough sequences to justify the grant of the claims sought.

As indicated, the instant specification is even more limited than the '008 patent because it describes only a single protein and no analogs or mutants thereof and, therefore, provides even less support than the '008 specification for claims of comparable scope and which were held to be invalid in that patent.

There are many factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is undue. These factors include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (FED. Cir. 1988).

All the Wands factors are considered and it is the balance of factors that determines whether a disclosure enables the use of the invention. It is acknowledged that the level of skill in the art is high. Although the specification on pages 12-16 discusses how variants can be made, the information is of a general nature. There are no working examples of any variants. From the teachings of the specification or the prior art, it is not predictable what changes could be made to the polypeptides that would result in the variants retaining TNF binding activity. For example, vertebrate growth hormone of 198 amino acids becomes an antagonist (inhibitor of growth) when a single amino acid is changed (Kopchick et al, U.S. Patent No. 5,350,836).

Art Unit: 1646

For the reasons discussed above, due to the large quantity of experimentation necessary to generate the infinite number of derivatives recited in the claims and possibly screen same for activity, the lack of direction/guidance presented in the specification regarding which structural features are required in order to provide activity, the absence of working examples, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the effects of mutation on protein structure and function, and the breadth of the claims, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

7.2 Claims 15-22, 45-48 and 50-53 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The specification describes a polypeptide sequence consisting of SEQ ID NO: 2 as well as the amino and carboxy terminal truncation/deletions variants of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18 and 20, all of which comprise the same core sequence of amino acids 41-201 of SEQ ID NO: 2 (which is SEQ ID NO: 4) and all of which are shown to have the activity of binding TNF. However, the claims as written include polypeptides comprising fragments and homologues, encompass polypeptides that vary substantially in length and also in amino acid composition. Due to unlimited changes, no conservation of structure is required. The instant disclosure of a core polypeptide, that of SEQ ID NO: 4 with the instantly disclosed specific activity, does not adequately support the scope of the claimed genus, which encompasses a substantial variety of subgenera. A genus claim may be supported by a representative number of species as set forth in *Regents of the*

*University of California v Eli Lilly & Co*, 119F3d 1559, 1569, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997), which states:

“To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that “the inventor invented the claimed invention”. Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1980) (“[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.”) Thus, an applicant complies with the written description requirement “by describing the invention, with all its claimed limitations, not that which makes it obvious,” and by using “such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.” Lockwood, 107 F.3d 1565, 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the ‘525 patent, “requires a precise definition, such as by structure, formula, chemical name, or physical properties,” not a mere wish or plan for obtaining the claimed chemical invention. Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, “an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself.” Id at 1170, 25 USPQ2d at 1606.”

A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus, or of a recitation of structural features common to the genus, which features constitute a substantial portion of the genus. The instant specification discloses, however, only polypeptides comprising the same core sequence SEQ ID NO: 4. Given the unpredictability of changing amino acids on the activities of proteins, and the fact that the specification fails to provide objective evidence that the additional sequences are indeed species of the claimed genus it

Art Unit: 1646

cannot be established that a representative number of species have been disclosed to support the genus claim.

***Priority***

8. This application is a continuation of 09/792,356, which is a continuation of 08/477,639, now patent 6,221,675, which is a division of 08/383,676, now patent 6,294,352, which is a continuation of 08,153,287, which is a continuation of 07/821,750, which is a division of 07/511,430. The Examiner notes that certified copies of the German priority documents P39 13 101.7, P3290 282.8 and European priority document 90106624.1 were provided in 07/511,430. However, Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

The second application must be an application for a patent for an invention which is also disclosed in the first application (the parent or provisional application); the disclosure of the invention in the parent application and in the second application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38F.3d551,32 USPQ 2d 1077 (Fed. Cir. 1994). The first priority document, 39 13 101.7, filed April 21, 1989, contains only fragments of the claimed polypeptides. The second priority document, 3920 282.8, filed June 21, 1989, discloses a polypeptide comprising amino acids 1-371 of the amino acid sequence of the full-length polypeptide of SEQ ID NO: 2. The third foreign priority document, 90106624.2, filed April 6, 1990, discloses the entire amino acid sequence of SEQ ID NO: 2 (455 amino acids). SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18 and 20 are contained within the first 201 amino acids of SEQ ID

Art Unit: 1646

NO: 2, therefore the priority date accorded to those sequences is June 21, 1989. However, the priority date for the full length protein of SEQ ID NO: 2 is April 6, 1990.

***Pertinent Art***

9. The art considered pertinent to the present application is Corti et al., Journal of Interferon and Cytokine Research, Vol. 15, pages 143-152 (1995), which teaches that the soluble urinary protein of the TNF receptor type I (the same proteins as those in the instant claims) are glycosylated differently from the same protein produced recombinantly by CHO cells, and have a different activity when produced recombinantly by *E. coli* cells (nonglycosylated form). Therefore, recombinantly produced soluble TNF receptor is distinct from that of naturally occurring soluble TNF receptor.

***Conclusion***

10. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (703) 308-3312. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers Before Final filed by RightFax should be directed to (703) 872-9306.

Official papers After Final filed by RightFax should be directed to (703) 872-9307.

Official papers filed by fax should be directed to (703) 308-4242.

Art Unit: 1646

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Eileen B. O'Hara, Ph.D.

A handwritten signature in cursive script that reads "Eileen B. O'Hara". The signature is written in black ink and is positioned below the printed name.

Patent Examiner